Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study
Language English Country England, Great Britain Media print-electronic
Document type Comparative Study, Journal Article, Randomized Controlled Trial
- Keywords
- Itraconazole, comparative bioavailability, generic drugs,
- MeSH
- Antifungal Agents administration & dosage pharmacokinetics MeSH
- Administration, Oral MeSH
- Adult MeSH
- Itraconazole administration & dosage analogs & derivatives pharmacokinetics MeSH
- Cross-Over Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Area Under Curve MeSH
- Half-Life MeSH
- Therapeutic Equivalency MeSH
- Capsules MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Antifungal Agents MeSH
- hydroxyitraconazole MeSH Browser
- Itraconazole MeSH
- Capsules MeSH
BACKGROUND: The aim of the study was to evaluate the bioequivalence of two itraconazole 100 mg capsule formulations. RESEARCH DESIGN AND METHODS: The single-center, open-label, randomized, three-period, three-sequence, reference-replicated, cross-over study included 38 healthy subjects under fed conditions. In each study period (separated by a 14-day washout), a single oral dose of the test (T) or reference (R) product was administered. Blood samples were collected at pre-dose and up to 72.0 h after administration. The calculated pharmacokinetic parameters, based on the plasma concentrations of itraconazole and hydroxy itraconazole, were AUC0-72h, AUC0-∝, Cmax, Tmax, T1/2 and Kel. RESULTS: The 90% CI for the test/reference geometric means ratio for the parent compound, itraconazole, was in the range from 85.29% to 116.07% for AUC0-72h. Since the coefficient of variation (CV) for the reference product was 44.95% for Cmax, the 90% CI for this parameter for itraconazole was 93.49-133.78%, which was within the proposed limits of the EMA for bioequivalence of 72.15-138.59%. During the study, 4 subjects encountered a total of 14 mild adverse events. CONCLUSIONS: The use of the reference-scaling approach with 3-period design (TRR, RTR, and RRT) was an efficient way to demonstrate that two commercially available oral itraconazole formulations met the predetermined bioequivalence criteria.
b Medical Faculty of the Military Medical Academy University of Defense in Belgrade Belgrade Serbia
c National Poison Control Centre Military Medical Academy Belgrade Serbia
Centre for Clinical Pharmacology Military Medical Academy Belgrade Serbia
References provided by Crossref.org
